Journal of The Korean Ophthalmological Society (대한안과학회지)

The Korean Ophthalmological Society (대한안과학회)
권호 표지

Therapeutic Effect of Topical Testosterone Gel in Patients with Dry Eye Syndrome

안구건조증 환자에서 국소 테스토스테론 젤의 치료효과

Heo, Hwan;Kang, In-Sung;Wu, Mei-Hwa;Yoon, Kyung-Chul
허환;강인성;오미화;윤경철

  • Published : 20060000
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the therapeutic effect of topical testosterone gel application to periocular area in dry eye. Methods: Thirty-four eyes of 17 patients with refractory dry eye were included. Five patients had Sjogren`s syndrome and 12 were non-Sjogren`s syndrome patients. Testosterone gel was applied on the periocular area three times a day. Symptom score corneal sensitivity test (CST), tear film break-up time (BUT), basal tear secretion test (BST), fluorescein staining, tear clearance test (TCR), and conjunctival impression cytology were checked and evaluated before, one month after and two months after treatment. Results: The mean symptom score before topical testosterone gel application was 3.44${\pm}$0.70; it was 2.88${\pm}$0.84 at 1 month after application and 2.03${\pm}$1.09 at 2 months after application. The improvement of tear film parameters including BUT, tear clearance rate, fluorescein staining score, conjunctival metaplasia and goblet cell density was statistically significant (P<0.05) at one and two months after treatment but neither BST nor CST was improved with statistically significance. There was no difference in the therapeutic effect of topical testosterone gel between Sjogren`s syndrome and non-Sjogren`s dry eye patients. Conclusions: The function of tear film and the integrity of ocular surface improved after topical application of testosterone gel in dry eye patients. Topical testosterone gel application may be an effective adjuvant therapy for the treatment of dry eye. J Korean Ophthalmol Soc 47(8):1259-1265, 2006

목적 : 안구건조증 환자에게 테스토스테론 젤을 국소적으로 안검주위에 사용한 후 그 치료효과를 알아보고자 하였다. 대상과 방법 : 기존 치료에 반응을 보이지 않는 심한 안구건조증 환자 17명, 34안(쇼그렌증후군 환자 5명 10안, 비쇼그렌증후군 환자 12명 24안을 대상으로 테스토스테론 젤을 안검주위에 1일 3회 도포하였고, 치료 전과 치료 1개월 및 2개월 후의 자각증상 점수, 각막감각검사, 눈물막파괴시간과 쉬르머검사, 눈물청소율, 형광염색을 통한 각막상피병증의 정도 및 결막의 압흔세포검사 등을 시행하여 그 효과를 평가하였다. 결과 : 안구건조증 환자에서 테스토스테론 젤을 국소적으로 사용하기 전과 사용 후 1개월 및 2개월의 자각 증상점수는 각각 3.44${\pm}$0.70, 2.88${\pm}$0.84, 2.03${\pm}$1.09 였으며, 각막감각검사 및 쉬르머검사를 제외한 눈물막파괴시간, 눈물청소율, 형광염색을 통한 각막상피병증의 정도 및 결막의 압흔세포검사상 술잔세포의 수와 편평상피화생 정도에서도 통계적으로 유의한 호전을 보였다. 쇼그렌증후군 환자군과 비쇼그렌증후군 환자군 간의 테스토스테론 젤의 치료 효과에 차이는 없었다. 결론 : 안구건조증 환자에서 국소 테스토스테론 요법은 안구표면과 눈물막 기능의 호전을 보여 안구건조증 환자에 있어서 보조적인 치료로서 효과적이라고 생각된다. <한안지 47(8):1259-1265, 2006>

Keywords

References

  1. Lemp MA. Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes. CLAO J 1995;21: 221-32
  2. Baudouin C. The pathology of dry eye. Surv Ophthalmol 2001;45:S211-20 https://doi.org/10.1016/S0039-6257(00)00200-9
  3. Gamache DA, Dimitrijevich SD, Weimer LK, et al. Secretion of proinflammatory cytokines by human conjunctival epithelial cells. Ocul Immunol Inflam 1997;5:117-28 https://doi.org/10.3109/09273949709085060
  4. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: A twenty-five-years review. Cornea 2000;19:644-9 https://doi.org/10.1097/00003226-200009000-00009
  5. Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 2004;88: 1467-74 https://doi.org/10.1136/bjo.2004.044347
  6. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmology 2004;15:299-304 https://doi.org/10.1097/00055735-200408000-00004
  7. Kim WJ, Lee JH. The effect of punctal occlusion in dry eye syndrome. J Korean Ophthalmol Soc 1990;31:851-6
  8. Smith RE. The tear film complex pathogenesis and emerging therapies for dry eyes. Cornea 2005;24:1-7 https://doi.org/10.1097/01.ico.0000141486.56931.9b
  9. Yoon KC, Im SK, Park YG, et al. Tear film and ocular surface changes after umbilical cord serum therapy in dry eye syndrome. Korean J Ophthalmol 2005;46:237-42
  10. Chia EM, Mitchell P, Rochtchina E, et al. Prevalence and associations of dry eye syndrome in an older population; the Blue-Mountains Eye Study. Clin Exp Ophthalmol 2003;37: 238-45
  11. Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136:318-26 https://doi.org/10.1016/S0002-9394(03)00218-6
  12. Talal N. Overview of Sjogren's syndrome. J Dent Res. 1987;66:672-4 https://doi.org/10.1177/00220345870660S111
  13. Thody AJ, Shuster S. Control and function of sebaceous glands. Physiol Rev 1989;69:383-416 https://doi.org/10.1152/physrev.1989.69.2.383
  14. Pochi PE, Stauss JS. Endocrinologic control of the development and activity of the human sebaceous gland. Invest Dermatol 1974;62:191-201 https://doi.org/10.1111/1523-1747.ep12676783
  15. Yamagami H, Schirra F, Liu M, et al. Androgen influence on gene expression in the meibomian gland. Adv Exp Med Biol 2002;506:477-81
  16. Sullivan DA, Edwards JA. Androgen stimulation of lacrimal gland function in mouse models of Sjogren's syndrome. J Steroid Biochem Mol Biol 1997;60:237-45 https://doi.org/10.1016/S0960-0760(96)00190-2
  17. Zeligs MA, Gordon K. Dehydroepiandrosterone therapy for the treatment of dry eye disorders. Int Patent Application WO 94/04155
  18. Taubota K. Tear dynamics and dry eye. Prog Retin Eye Res 1998;17:565-96 https://doi.org/10.1016/S1350-9462(98)00004-4
  19. Nelson JD. Impression cytology. Cornea 1988;7:71-81
  20. Sator MO, Joura EA, Golaszewski T, et al. Treatment of menopausal keratoconjunctivitis sicca with topical oestradiol. Br J Obstet Gynaecol 1998;105:100-2 https://doi.org/10.1111/j.1471-0528.1998.tb09358.x
  21. Pochi PE, Strauss JS. Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol 1974;62:191-201 https://doi.org/10.1111/1523-1747.ep12676783
  22. Schaumberg DA, Buring JE, Sullivan DA. Dana MR. Hormone replacement therapy and the prevalence of dry eye syndrome. JAMA 2001;286:2114-9 https://doi.org/10.1001/jama.286.17.2114
  23. Orth DN, Kovacs WJ. The adrenal cortex In : Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology. Philadelphia: W.B Saunders, 1998:517-664
  24. Rocha EM, Wickham LA, da Silveira LA, et al. Identification of androgen receptor protein and 5 alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol 2000;84:76-84 https://doi.org/10.1136/bjo.84.1.76
  25. Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab 2000;85:4874-82 https://doi.org/10.1210/jc.85.12.4874
  26. Sullivan DA, Block L, Pena JD. Influence of androgens and pituitary hormones on the structural profile and secretory activity of the lacrimal gland. Acta Ophthalmol Scand 1996;74:421-35 https://doi.org/10.1111/j.1600-0420.1996.tb00594.x
  27. Azzarolo AM, Mircheff AK, Kaswan RL, et al. Androgen support of lacrimal gland function. Endocrine 1997;6:39-45 https://doi.org/10.1007/BF02738800
  28. Sullivan DA, Allansmith MR. Homonal influence on the secretory immune system of the eye: androgen modulation of IgA levels in tears of rats. J Immunol 1985;134:2978-82
  29. Sato EH, Sullivan DA. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjogren's syndrome. Invest Ophthalmol Vis Sci 1994;35: 2632-42
  30. Sullivan DA, Sullivan BD, Ullman MD, et al. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci 2000;41:3732-42
  31. Sato EH, Ariga H, Sullivan DA. Impact of androgen therapy in Sjogren's syndrome: hormonal influence on lymphocyte populations and Ia expression in lacrimal glands of MRL/Mp-lpr/lpr mice. Invest Ophthalmol Vis Sci 1992;33: 2537-45